292 related articles for article (PubMed ID: 30460992)
1. Pediatric Anthracycline-Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem-Cell Modeling.
Tripaydonis A; Conyers R; Elliott DA
Clin Pharmacol Ther; 2019 Mar; 105(3):614-624. PubMed ID: 30460992
[TBL] [Abstract][Full Text] [Related]
2. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
[TBL] [Abstract][Full Text] [Related]
3. Anthracycline-Induced Cardiotoxicity: Molecular Insights Obtained from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs).
Bozza WP; Takeda K; Alterovitz WL; Chou CK; Shen RF; Zhang B
AAPS J; 2021 Mar; 23(2):44. PubMed ID: 33719006
[TBL] [Abstract][Full Text] [Related]
4. Use of hiPSC to explicate genomic predisposition to anthracycline-induced cardiotoxicity.
Magdy T; Burridge PW
Pharmacogenomics; 2021 Jan; 22(1):41-54. PubMed ID: 33448871
[TBL] [Abstract][Full Text] [Related]
5. Preventing Anthracycline-Induced Cardiotoxicity Using Functional Genomics and Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Lo Sardo V; Kamp TJ
Circulation; 2022 Jan; 145(4):295-298. PubMed ID: 35073175
[No Abstract] [Full Text] [Related]
6. Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells.
Takeda M; Miyagawa S; Fukushima S; Saito A; Ito E; Harada A; Matsuura R; Iseoka H; Sougawa N; Mochizuki-Oda N; Matsusaki M; Akashi M; Sawa Y
Tissue Eng Part C Methods; 2018 Jan; 24(1):56-67. PubMed ID: 28967302
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the molecular mechanisms underlying azithromycin-induced cardiotoxicity using human-induced pluripotent stem cell-derived cardiomyocytes.
Wang X; Pan Z; Wang J; Wang H; Fan H; Gong T; Sun Q; Feng Y; Liang P
Clin Transl Med; 2021 Sep; 11(9):e549. PubMed ID: 34586730
[No Abstract] [Full Text] [Related]
8. Circulating microRNAs: Potential Markers of Cardiotoxicity in Children and Young Adults Treated With Anthracycline Chemotherapy.
Leger KJ; Leonard D; Nielson D; de Lemos JA; Mammen PP; Winick NJ
J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28377429
[TBL] [Abstract][Full Text] [Related]
9. Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study.
Brown TR; Vijarnsorn C; Potts J; Milner R; Sandor GG; Fryer C
Pediatr Blood Cancer; 2013 May; 60(5):842-8. PubMed ID: 23382019
[TBL] [Abstract][Full Text] [Related]
10. Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity.
Meiners B; Shenoy C; Zordoky BN
Biol Sex Differ; 2018 Aug; 9(1):38. PubMed ID: 30157941
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?
Sawyer DB; Peng X; Chen B; Pentassuglia L; Lim CC
Prog Cardiovasc Dis; 2010; 53(2):105-13. PubMed ID: 20728697
[TBL] [Abstract][Full Text] [Related]
12. [Cardiotoxicity of anthracyclines].
Costache II; Petriş A
Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1200-7. PubMed ID: 22276470
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic testing to guide therapeutic decision-making and improve outcomes for children undergoing anthracycline-based chemotherapy.
Loucks CM; Yan K; Tanoshima R; Ross CJD; Rassekh SR; Carleton BC
Basic Clin Pharmacol Toxicol; 2022 Jan; 130 Suppl 1():95-99. PubMed ID: 33900042
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children.
Sherief LM; Kamal AG; Khalek EA; Kamal NM; Soliman AA; Esh AM
Hematology; 2012 May; 17(3):151-6. PubMed ID: 22664114
[TBL] [Abstract][Full Text] [Related]
15. Bringing in vitro analysis closer to in vivo: Studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling.
Verheijen M; Schrooders Y; Gmuender H; Nudischer R; Clayton O; Hynes J; Niederer S; Cordes H; Kuepfer L; Kleinjans J; Caiment F
Toxicol Lett; 2018 Sep; 294():184-192. PubMed ID: 29803840
[TBL] [Abstract][Full Text] [Related]
16. Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicity.
Sirenko O; Cromwell EF; Crittenden C; Wignall JA; Wright FA; Rusyn I
Toxicol Appl Pharmacol; 2013 Dec; 273(3):500-7. PubMed ID: 24095675
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.
Lee S; Lee HA; Choi SW; Kim SJ; Kim KS
Toxicol Appl Pharmacol; 2016 Apr; 296():42-53. PubMed ID: 26821276
[TBL] [Abstract][Full Text] [Related]
18. Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes.
Matsui T; Miyamoto K; Yamanaka K; Okai Y; Kaushik EP; Harada K; Wagoner M; Shinozawa T
Toxicol Appl Pharmacol; 2019 Nov; 383():114761. PubMed ID: 31533062
[TBL] [Abstract][Full Text] [Related]
19. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
Yang X; Papoian T
J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
[TBL] [Abstract][Full Text] [Related]
20. New signal transduction paradigms in anthracycline-induced cardiotoxicity.
Ghigo A; Li M; Hirsch E
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1916-25. PubMed ID: 26828775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
